
Companies - June 5, 2015
AZ Pondering Future of Psoriasis Drug
AstraZeneca will need to decide soon whether to independently pursue an experimental psoriasis drug that has been linked to suicidal side effects, Bloomberg reported recently. “We want to take more time to look at the data and take time to engage with regulators,” AstraZeneca’s Chief Executive Officer Pascal Soriot told the news service about brodalumab. “We are actively contacting people who […]

Collaboration - May 27, 2015
Amgen, AZ End Psoriasis Drug Deal
Amgen is dissolving an agreement with AstraZeneca to develop the psoriasis drug brodalumab after a patient involved in a late-stage trial developed suicidal thoughts and behavior, according to BioSpace.com. Because of that incident, if the drug were eventually approved by regulators, they would likely require restrictive labeling, which discouraged Amgen. The latest news came as […]

Collaboration - April 24, 2015
AZ, Amgen Switch to Psoriasis
Amgen and partner AstraZeneca are preparing to deliver U.S. and European applications for their plaque psoriasis drug brodalumab by midyear. The two companies halted tests for brodalumab as an asthma medication. Amgen outlined the news in its quarterly report, which also notes a 14 percent drop in R&D spending. “Based on the recommendation of an […]